Safety and efficacy of Glecaprevir / Pibrentasvir combination therapy for chronic hepatitis C - including hemodialysis patients
Not Applicable
- Conditions
- Patients with chronic hepatitis C patients and patients with type C compensated cirrhosis
- Registration Number
- JPRN-UMIN000032073
- Lead Sponsor
- ippon Medical School Chiba Hokusoh Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
Not provided
Exclusion Criteria
1.History of allergy to Glecaprevir / Pibrentasvir 2.Severe liver dysfunction 3.pregnant woman or lactating mother 4.Hepatocellular carcinoma, or other malignant tumor. 5.severe depression 6.Judged by investigator not to be appropriate for inclusion in this study 7.Receiving contraindicated drugs for Glecaprevir and Pibrentasvir combined therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SVR 12 rate
- Secondary Outcome Measures
Name Time Method 1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration. 4. Drug concentration after administration in hemodialysis patients.